%0 Journal Article
%T Real world effectiveness of repeated ketamine infusions for treatment resistant bipolar depression
%J Bipolar disorders
%D 2022
%A Fancy, Farhan
%A Rodrigues, Nelson B.
%A Di Vincenzo, Joshua D.
%A Chau, Edmond H.
%A Sethi, Rickinder
%A Husain, Muhammad I.
%A Gill, Hartej
%A Tabassum, Aniqa
%A Mckenzie, Andrea
%A Phan, Lee
%A McIntyre, Roger S.
%A Rosenblat, Joshua D.
%V ePub
%N ePub
%P ePub-ePub
%X BACKGROUND: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. <br><br>METHODS: This study was conducted in a community clinic in Mississauga, Ontario (Canadian Rapid Treatment Centre of Excellence; Braxia Health). In this observational study (NCT04209296), patients with treatment-resistant bipolar I/II depression (n=66) received four sub-anesthetic doses of IV ketamine (0.5-0.75mg/kg) over a two-week period. Symptoms of depression, suicidality, anxiety and functioning were assessed with validated self-report measures. <br><br>RESULTS: Statistically and clinically significant antidepressant effects were observed in the overall sample, as measured by the Quick Inventory for Depression Symptomatology-Self Report-16 (QIDS-SR(16) ) with further reductions in depressive symptoms observed after each subsequent infusion (n=66; mean QIDS-SR(16) reduction of 6.08+/-1.39; p < 0.0001). Significant reductions of suicidal thoughts (QIDS-SR(16) -Suicide Item) and anxiety (Generalized Anxiety Disorder-7) were also observed with functional improvements on the Sheehan Disability Scale (p < 0.0001 on all measures). Moreover, the response rate (QIDS-SR16 total score decrease ≥ 50% from baseline) was 35% and remission rate (QIDS-SR16 total score ≤5) was 20% after four infusions. Infusions were generally well tolerated with treatment-emergent hypomania observed in only three patients (4.5%) with zero cases of mania or psychosis. <br><br>CONCLUSIONS: Real world effectiveness of IV ketamine for bipolar depression was observed. Repeated doses were associated with greater symptom reduction and adequate tolerability.<p /> <p>Language: en</p>
%G en
%I John Wiley and Sons
%@ 1398-5647
%U http://dx.doi.org/10.1111/bdi.13284